Related by context. All words. (Click for frequent words.) 77 PSA nadir 75 biochemical recurrence 74 CR nPR 74 pT3 74 #.#ng/ml 74 NMIBC 73 PSADT 73 advanced adenoma 73 relapsed MM 73 progression TTP 73 pCR 72 colorectal adenoma 72 histologically confirmed 72 underwent surgical resection 72 FOLFOX4 72 CCyR 72 HBeAg 72 nonmetastatic 72 lymphocytosis 72 % CI #.#-#.# [003] 72 HBeAg seroconversion 71 underwent resection 71 detectable HCV RNA 71 metastatic malignant 71 CR CRu 71 severe neutropenia 71 mg/m2 dose 71 evaluable subjects 71 clodronate 71 preoperative PSA 71 8mg/kg 71 Flu Cy 71 #Gy 71 neurologic progression 71 papillary renal cell carcinoma 71 radical prostatectomy RP 71 Kaplan Meier analysis 71 REYATAZ r arm 71 mg kg dose 70 locoregional recurrence 70 pT2 70 debulking surgery 70 stage IIIb IV 70 mL/min/#.# m 2 70 lumbar spine BMD 70 % CI #.#-#.# [007] 70 achieved ACR# 70 % Confidence Interval 70 neoadjuvant therapy 70 curative resection 70 complete cytogenetic response 70 operable breast cancer 70 flutamide 70 binary restenosis 70 HBeAg positive patients 70 recurrent glioblastoma multiforme 70 HBeAg negative patients 70 undetectable HBV DNA 70 chemoradiation therapy 69 achieved CCyR 69 postoperative chemotherapy 69 ALT elevation 69 posttreatment 69 TIMP 69 virological response 69 nondiabetic patients 69 extracapsular extension 69 prostate carcinoma 69 Median progression 69 remission CR 69 partial remissions 69 neoadjuvant 69 lopinavir r arm 69 PRADAXA #mg 69 adjuvant radiotherapy 69 CIN3 69 morphometric vertebral fractures 69 5-FU/LV 69 serum cortisol 69 IU ml 69 TURBT 69 interferon ribavirin 69 alanine aminotransferase ALT 69 ertapenem 69 4mg/kg 69 virologic failure 69 neoadjuvant chemotherapy 69 specific antigen PSA 69 prostate cancer CaP 69 #mg QD [002] 69 advanced adenomas 69 FluCAM arm 69 HGPIN 69 androgen deprivation 69 hepatocellular carcinomas 69 #mg BID [001] 69 postintervention 69 log# copies mL 69 nodal metastasis 69 seminal vesicle invasion 68 P = .# 68 distant metastasis 68 VELCADE melphalan 68 endometrial carcinoma 68 hypophosphatemia 68 PEG IFN 68 KRAS mutations occur 68 seropositivity 68 baseline LDH 68 multivariate Cox 68 SUVmax 68 CIN2 + 68 EDSS scores 68 dosing cohort 68 antithymocyte globulin 68 leucopenia 68 microgram kg 68 glycated hemoglobin levels 68 colorectal carcinoma 68 complete cytogenetic 68 CRp 68 Partial Response 68 Partial Responses 68 adjuvant radiation 68 mitoxantrone plus 68 cGy 68 radiotherapy RT 68 adjuvant cisplatin 68 antiretroviral naïve 68 Doxil ® 68 5-fluorouracil/leucovorin 68 HER2 expression 68 μmol L 68 chemoradiotherapy 68 adriamycin 68 oral clodronate 68 histological subtype 68 progesterone receptor negative 68 sustained virological response 68 nadroparin 68 octreotide LAR 68 renal cell carcinomas 68 posttransplant 68 haematologic 68 thyroglobulin 68 μg liter 68 receiving VICTRELIS 68 CC genotype 68 cytoreduction 68 recurrent VTE 68 serum testosterone 68 estramustine 68 Subgroup analysis 68 serum concentrations 68 mesalamine granules 68 definite stent thrombosis 68 invasive carcinomas 68 hematologic toxicity 68 EBRT 68 mIU ml 68 recurrent metastatic 68 mutated KRAS 68 lymphocyte count 68 baseline HbA1c 68 RECIST criteria 67 genotypic resistance 67 ritonavir boosted 67 Folfox 67 mg m² 67 prior chemotherapy regimens 67 histologically proven 67 F FDG PET 67 preoperative chemotherapy 67 visceral metastases 67 elevated transaminases 67 TRAIL R1 67 clinically localized prostate 67 Pegasys plus Copegus 67 nodular partial response 67 QTcF 67 PegIFN RBV 67 K ras mutations 67 metastatic GIST 67 preintervention 67 leukemia AML 67 evaluable 67 TIMP 1 67 log# reduction 67 HBeAg negative 67 interquartile range 67 perioperative complications 67 baseline Hb 67 virologic response 67 oblimersen 67 PREZISTA r arm 67 completely resected 67 refractory ischemia 67 mg QD 67 bortezomib refractory 67 nutlin 3a 67 HBV DNA 67 advanced neoplasia 67 lactate dehydrogenase LDH 67 confidence interval #.#-#.# 67 pg ml 67 doxorubicin cyclophosphamide 67 intact parathyroid hormone 67 postoperative morbidity 67 elevated ALT 67 atazanavir ritonavir 67 Mitomycin C 67 radiochemotherapy 67 cisplatin chemotherapy 67 response CCyR 67 HIV RNA 67 asymptomatic carotid stenosis 67 radioiodine therapy 67 FUSILEV enhances 67 Thal Dex 67 % CI #.#-#.# [008] 67 metastatic bladder 67 liver histology 67 hepatic resection 67 prednisone prednisolone plus 67 5FU 67 SGPT 67 malignant neoplasm 67 liver metastasis 67 thymoma 67 anthracycline taxane 67 lactate dehydrogenase 67 urinary N telopeptide 67 rFSH 67 NNRTI resistance 67 BARACLUDE ® 67 locoregional disease 67 total thyroidectomy 67 ER CHOP 67 Response Evaluation Criteria 67 FOLPI 67 pmol L 67 elevated LDH 67 unresectable tumors 67 T1c 67 comparator arm 67 mCi 67 neutrophil counts 67 iPTH 67 HbA 1c levels 67 CIMZIA TM 67 resected pancreatic cancer 67 â ‰ ¥ 67 ovarian carcinoma 67 lung metastases 67 serum urate 67 FOLFIRI alone 67 ug dose 67 resistant hormone refractory 67 bladder carcinoma 67 underwent radical prostatectomy 67 undergone radical prostatectomy 67 DLTs 67 postoperative complication 67 hepatic metastases 67 serum IGF 67 Median PFS 67 Index CDAI 66 #ng/ml 66 euthyroid 66 mcg albinterferon alfa 2b 66 chlorambucil 66 aminotransferases 66 neutropenic sepsis 66 prospectively stratified 66 paraprotein 66 pancreatic resection 66 ASCUS 66 cytoreductive surgery 66 acute GvHD 66 creatinine ratio 66 Adjuvant chemotherapy 66 dalteparin 66 -#.# log# 66 univariate analysis 66 dacarbazine DTIC 66 ALT normalization 66 MCyR 66 alanine aminotransferase 66 Papillary 66 mg qd 66 undetectable virus HCV 66 p = #.# [003] 66 grade squamous intraepithelial 66 serum aminotransferase levels 66 Free Survival PFS 66 OGTT 66 rapid virologic response 66 antibody titer 66 CsA 66 p = NS 66 underwent liver transplantation 66 abnormal cytology 66 placebo dexamethasone 66 biologic DMARD 66 infliximab monotherapy 66 mg ustekinumab 66 CI #.#-#.# [001] 66 tumor recurrence 66 adjunctive placebo 66 achieved sustained virological 66 plus dexamethasone 66 invasive aspergillosis 66 metastatic malignant melanoma 66 fibrinolysis 66 HSCT 66 clinicopathological features 66 reinfarction 66 cisplatin gemcitabine 66 mg/m2/day 66 moderately emetogenic 66 anti HBs 66 distant metastases 66 recurrent NSCLC 66 node metastases 66 cyclophosphamide methotrexate 66 tipranavir r 66 graft occlusion 66 pamidronate 66 FOLFOX6 66 urothelial carcinoma 66 generalized edema 66 sUA 66 cystectomy 66 ribavirin RBV 66 patients evaluable 66 concurrent chemoradiation 66 squamous histology 66 adenoma recurrence 66 histologic subtype 66 total abdominal hysterectomy 66 APTIVUS r 66 EGFR TKI 66 dose cohort 66 blastic phase 66 PASI scores 66 metastatic lesions 66 angiographic restenosis 66 Asymptomatic 66 intratumoral 66 vincristine doxorubicin 66 external beam radiotherapy 66 undetectable HCV RNA 66 fosamprenavir 66 Operative mortality 66 nmol liter 66 multivariable analysis 66 dosing cohorts 66 #mg/m# [002] 66 symptomatic VTE 66 lymphadenectomy 66 cisplatin vinorelbine 66 pelvic lymphadenectomy 66 endometrial hyperplasia 66 salpingo oophorectomy 66 annualized relapse 66 hematological parameters 66 Stage IIIb 66 telaprevir dosed 66 atypical hyperplasia 66 Peg IFN 66 aspartate aminotransferase 66 liver resection 66 Radical prostatectomy 66 TP# mutations 66 cytogenic 66 Ejection Fraction 66 hours postdose 66 mitoxantrone chemotherapy 66 paclitaxel cisplatin 66 pancreatic adenocarcinoma 66 mcg kg 66 BRCA2 mutation carriers 66 genotype 1b 66 serum calcium levels 66 GnRH agonist 66 leukocyte count 66 prostate adenocarcinoma 66 epithelial ovarian 66 RECIST Response Evaluation Criteria 66 severe exacerbations 66 PCa 66 mcg BID 66 gemcitabine cisplatin 66 deep venous thromboses 66 mutated K ras 66 metastatic pancreatic 66 lymph node metastasis 66 peritoneal cancer 66 #mg/m# [001] 66 ErbB2 positive 66 Postoperative complications 66 aspartate aminotransferase AST 66 nicardipine 66 ipsilateral stroke 66 cytogenetic response 66 cEVR 66 highly emetogenic 66 ara C 66 IELT 65 FDG-PET/CT 65 plus methotrexate 65 timepoints 65 platelet reactivity 65 Immunohistochemical staining 65 locoregional 65 postoperative mortality 65 Allogeneic 65 median PFS 65 -#.# ± [002] 65 nonvertebral fractures 65 nephrectomy 65 hemoglobin Hb 65 adrenalectomy 65 serum phosphate 65 DAS# CRP 65 LEXIVA r 65 Platinol ® cisplatin 65 cTnI 65 aPTT 65 Solid Tumors criteria 65 p = .# [002] 65 cervical carcinoma 65 Crohn Disease Activity 65 sustained virologic response 65 stage IIIB 65 LV dysfunction 65 mucosal inflammation 65 abnormal p# biomarker 65 adjuvant tamoxifen 65 alfa 2a 65 ischemia driven 65 KRAS mutant tumors 65 CIMZIA ™ 65 BENICAR HCT 65 neutropaenia 65 fluorouracil leucovorin 65 ug kg 65 postmenopausal osteoporotic women 65 pegylated liposomal doxorubicin 65 esophageal carcinoma 65 radical nephrectomy 65 q#h 65 serum prostate 65 Target Lesion Revascularization TLR 65 azacytidine 65 underwent radical cystectomy 65 XIENCE V demonstrated 65 MBq 65 timepoint 65 bronchoalveolar lavage 65 grade cervical intraepithelial 65 Ishak fibrosis score 65 median survivals 65 MMSE score 65 tumor resection 65 FOLFOX4 alone 65 mild renal insufficiency 65 electrical cardioversion 65 DAS# remission 65 cranial irradiation 65 advanced hepatocellular carcinoma 65 vaginal hysterectomy 65 mucosal healing 65 corticosteroid dose 65 Arch Intern Med 65 androgen suppression 65 EDSS score 65 Kaplan Meier estimate 65 mg TID 65 chemo radiotherapy 65 serum creatinine levels 65 methotrexate monotherapy 65 moderate renal impairment 65 pg mL 65 invasive ductal 65 Pharmacokinetics PK 65 μg kg 65 tPSA 65 HER2 overexpression 65 NATRECOR ® 65 glomerular filtration 65 basal cell carcinoma BCC 65 iniparib BSI 65 metastatic renal cell carcinoma 65 allogeneic SCT 65 aged ≥ 65 Fluorouracil 65 ABVD 65 concomitant antibiotics 65 neoadjuvant treatment 65 mU liter 65 postop 65 μg ml 65 keloid scarring 65 daunorubicin 65 HBsAg 65 cisplatin resistant 65 cis retinoic acid 65 abacavir lamivudine 65 Stage IIB 65 Retreatment 65 hip BMD 65 rebleeding 65 hematological relapse 65 subcutaneous enoxaparin 65 cytogenetic responses 65 dapagliflozin plus 65 saline placebo 65 adenotonsillectomy 65 preoperative radiotherapy 65 pancreatic carcinoma 65 ALND 65 perioperative mortality 65 minimally symptomatic 65 nonischemic 65 biliary tract cancer 65 hepatectomy 65 breast carcinoma 65 urine albumin 65 Follicular Lymphoma 65 administered subcutaneously 65 daily subcutaneous injections 65 prospectively defined 65 lispro 65 x ULN 65 peritoneal carcinomatosis 65 Endometrial 65 5 Fluorouracil 65 CLL SLL 65 cervical intraepithelial neoplasia 65 ERCC1 65 Secondary endpoints included 65 Infusion Reactions Severe 65 postprocedure 65 radical retropubic prostatectomy 65 R# #mg BID 65 non splenectomized 65 heavily pretreated patients 65 VFEND 65 gefitinib Iressa 65 mCRC patients 65 MADRS score 65 hsCRP levels 65 castrate resistant 65 postoperative radiotherapy 65 mL/min/#.# m2 65 serum HCV RNA 65 spirometric 65 bleomycin 65 isoprostane 65 atrophic gastritis 65 SLNB 65 undergoing radical cystectomy 65 serum urate levels 65 tirofiban 65 mIU L 65 AVODART 65 Ceplene/IL-2 65 serum PSA 65 ximelagatran 65 refractory NSCLC 65 autoantibody positive 65 unresectable stage 65 nab paclitaxel 65 metastatic gastric 65 everolimus eluting stents 65 tenecteplase 65 colorectal neoplasms 65 β blockers 65 TAXUS Express Stent 65 subtrochanteric 65 biopsy Gleason 65 Pegylated Liposomal Doxorubicin 65 Hypotension 65 beta blocker therapy 65 BRCA1 mutation carriers 65 serum HBV DNA 65 rFVIIa 65 pulmonary exacerbation 65 perioperatively 65 Pegylated Interferon 65 nadolol 65 piperacillin tazobactam 65 fallopian tube carcinoma 65 paricalcitol 65 undetectable viral 65 hematopoietic cancers 65 calculated creatinine clearance 65 serum estradiol 65 renal tumors 65 weekly subcutaneous injections 65 immunostaining 65 parathyroidectomy 65 KRAS mutations 65 allogeneic stem cell 65 secondary efficacy endpoint 65 amoxicillin clavulanate 65 #mg dose [002] 65 treatment naive genotype 65 Hormone Refractory Prostate Cancer 65 aminotransferase levels 64 p#HER# positive 64 hepatitis C genotype 64 ug ml 64 clinically meaningful improvement 64 elevated troponin 64 CYT# potent vascular disrupting 64 transrectal ultrasound guided 64 histologically 64 hepatorenal syndrome 64 Hb A1C 64 PLX STROKE targeting 64 XIENCE V PROMUS Stent 64 myocardial necrosis 64 resectable 64 response pCR 64 nonfatal MI 64 N telopeptide 64 thrombocytopenic 64 androgen ablation 64 R0 resection 64 tumors GIST 64 Bezielle 64 PREZISTA ritonavir 64 busulfan 64 % CI #.#-#.# [005] 64 neutrophil count 64 FLT3 ITD 64 remission induction 64 NSTE ACS 64 confirmed CCyR 64 lymph node involvement 64 HBeAg positive 64 surgically resected 64 LHRH receptor positive 64 certolizumab 64 ALT flares 64 IFN α 64 aminotransferase 64 eplerenone 64 -#.# log# copies mL 64 severe oral mucositis 64 Hurthle cell 64 axillary nodes 64 recurrent UTI 64 HBV DNA levels 64 lymph node metastases 64 axillary node 64 chronic HCV genotype 64 idiopathic PAH 64 receiving golimumab 64 gemcitabine carboplatin 64 axillary lymph nodes 64 #mg q8h 64 HNSCC 64 ACR# responses 64 thyroid carcinoma 64 Immunohistochemical analysis 64 rosuvastatin #mg 64 Kaplan Meier method 64 intermittent dosing 64 hyperphenylalaninemia HPA due 64 GOUT 64 PREZISTA r 64 STRIDE PD 64 bronchoalveolar lavage fluid 64 colorectal adenocarcinoma 64 cutaneous melanoma 64 Natalizumab 64 tinzaparin 64 BEACOPP 64 fluorouracil 64 mucinous 64 nonobstructive CAD 64 MACCE 64 lopinavir r 64 PSMA ADC 64 virological failure 64 basal cell skin 64 pneumonectomy 64 resected 64 lymphocyte counts 64 #.#g/day 64 Postoperative 64 colectomy 64 bone metastasis 64 gastric adenocarcinoma 64 atrioventricular block 64 plasma HCV RNA 64 ABCB1 64 symptomatic intracranial hemorrhage 64 dexamethasone Decadron 64 imatinib therapy 64 Histological 64 graft dysfunction 64 surgical debulking 64 adefovir treated 64 papillary thyroid carcinoma 64 ACTEMRA TM 64 transvaginal sonography 64 plasma uric acid 64 intravenous bolus 64 carotid stenosis 64 acromegalic patients 64 epithelial ovarian cancer 64 parathyroid carcinoma 64 endoscopic remission 64 tumor progression TTP 64 adjuvant hormonal therapy 64 aplastic anemia AA 64 B7 H3 64 #mg/day [002] 64 Hazard Ratio 64 trastuzumab Herceptin ® 64 multivariable adjusted 64 Kaplan Meier 64 troponin T 64 prednisone prednisolone 64 GG genotype 64 chemotherapy cisplatin 64 ribavirin therapy 64 mediastinitis 64 FOLFIRI 64 adnexal mass 64 precursor lesions 64 recurrent venous thromboembolism 64 IL#B 64 recovery CRp 64 tumor necrosis 64 oral allopurinol 64 baseline FEV 64 docetaxel chemotherapy 64 relapsed ALL 64 myeloablative 64 Plasma concentrations 64 metastatic carcinoid tumors 64 bronchoalveolar lavage BAL 64 transplant ASCT 64 PROSTVAC VF 64 radiographic progression 64 % CI #.#-#.# [006] 64 prostate cancer PCa 64 MS relapses 64 elevated creatinine 64 undetectable PSA 64 paclitaxel carboplatin 64 hA# 64 overt nephropathy 64 serum phosphorous 64 resectable pancreatic cancer 64 tumor regressions 64 sarcomatoid 64 decitabine 64 lesional 64 NIHSS 64 T1a 64 MGd 64 CI -#.# 64 Prostate specific antigen 64 LV ejection fraction 64 cytokeratin 64 cytoreductive nephrectomy 64 Solid Tumors RECIST 64 steroid dexamethasone 64 taxane chemotherapy 64 evaluable patients 64 leiomyomas 64 + PH# 64 undergone splenectomy 64 postinjury 64 taxane chemotherapy administered 64 cilostazol 64 splenectomized patients 64 SCr 64 mitomycin C 64 heterozygotes 64 serum albumin 64 sUA levels 64 diabetes mellitus DM 64 autologous SCT 64 elevated serum creatinine 64 TLUS 64 radical cystectomy 64 hormone receptor negative 64 Virologic 64 antiangiogenic therapy 64 virologic responses 64 urothelial cancer 64 Index CDAI score 64 thalidomide Thalomid 64 receiving highly emetogenic 64 Myelodysplastic Syndrome MDS 64 pathologic diagnosis 64 budesonide pMDI 64 TAXUS p value 64 Circulating tumor cells 64 myelodysplastic myeloproliferative diseases 64 eosinophil count 64 gemcitabine Gemzar ® 64 endometrial thickness 64 reflux esophagitis 64 mcg QD 64 adenomatous polyps 64 metaplasia 64 multivariate adjustment 64 FDG uptake 64 metastatic lung cancer 64 neutropenia dehydration dyspnea 64 histopathologic examination 64 intravesical chemotherapy 64 pmol liter 64 #mg dosing group 64 undergoing coronary angiography 64 vasopressor 64 HBeAg + 64 oral prednisone 64 multivariate analyzes 64 CMV infection 63 HIV uninfected 63 triiodothyronine 63 TMC# r 63 chronic GVHD 63 needle aspiration 63 Platinol ® 63 splenectomized 63 #.#mg/dL 63 treatment naïve genotype 63 breast carcinomas 63 oxycodone CR 63 metastatic RCC 63 glycosylated hemoglobin HbA1c 63 coronary stenosis 63 ALA PDT 63 mg/m2 IV 63 gemcitabine Gemzar 63 hemoglobin A1c HbA1c 63 Cystectomy 63 QD dosing 63 unstable angina pectoris 63 CDAI 63 HCV genotype 63 standard chemotherapy regimen 63 EXJADE 63 intravesical therapy 63 nonmelanoma skin cancers 63 somatostatin analog 63 IFN beta 63 protein excretion 63 orchiectomy 63 ng dL 63 carboplatin paclitaxel 63 tipranavir ritonavir 63 neoplastic cells 63 allogeneic hematopoietic stem cell 63 nonresponders 63 gout flares 63 CIMZIA TM certolizumab pegol 63 osteopenic 63 colorectal liver metastases 63 GH deficiency 63 T2DM 63 3mg/kg 63 colorectal cancer liver metastases 63 gastric carcinoma 63 periprocedural 63 liver metastases 63 locoregional control 63 Patients Receiving 63 epithelial tumors 63 KRAS wild 63 follicular lymphomas 63 extracolonic findings 63 CHOP chemotherapy 63 EUS FNA 63 intravenous bisphosphonates 63 low dose cytarabine 63 Am J Cardiol 63 XELOX 63 BCG vaccinated 63 thrombocytosis 63 IFN alfa 63 Peginterferon 63 Acute Myeloid Leukaemia AML 63 Kaplan Meier estimates 63 Kinoid 63 localized renal 63 HCV Genotype 63 stage IIIA 63 doxorubicin docetaxel 63 MAGE A3 ASCI 63 Psoriasis Area 63 neoplasias 63 achieved PASI 63 cancer mCRC 63 TT genotype 63 Pemetrexed 63 hemoglobin A1c levels 63 carcinoembryonic antigen 63 umol L 63 interleukin IL -# 63 p ≤ 63 bacillus Calmette Guerin 63 goserelin 63 undergoing radical prostatectomy 63 benign nodules 63 anaplastic astrocytomas 63 vitamin B# folic acid 63 neoadjuvant radiation 63 Waldenstrom macroglobulinemia 63 lenalidomide Revlimid R 63 MGUS 63 #mmHg [001] 63 anastrazole 63 atorvastatin #mg 63 Hazard Ratio HR 63 ALT elevations 63 pleurodesis 63 malignancy HCM 63 estimated glomerular filtration 63 NPH insulin 63 Castration Resistant Prostate Cancer 63 chronic eosinophilic leukemia 63 endoscopic resection 63 recurrent DVT 63 plasma cortisol 63 FluCAM 63 #mg ATC 63 μg dL 63 primary patency 63 Postoperatively 63 ug mL 63 REMICADE monotherapy 63 lymph node dissection 63 anastomotic leak 63 axillary node dissection 63 unfractionated heparin UFH 63 tumor xenograft models 63 chemoresistant 63 Lupuzor ™ 63 desvenlafaxine succinate 63 confidence interval CI 63 ductal cancer 63 Viread Emtriva Sustiva 63 Peginterferon Alfa 2a 63 artery stenosis 63 TNF antagonist 63 fasting plasma glucose FPG 63 T1DM 63 cerebral vasospasm 63 FDG PET imaging 63 experienced virologic failure 63 receiving PEGINTRON 63 transaminase levels 63 ABC/3TC 63 gadolinium enhanced 63 tamoxifen therapy 63 edifoligide 63 Adenomas 63 TOP2A 63 teriflunomide 63 anthracycline containing 63 ipsilateral breast 63 inotropic 63 leukocyte counts 63 adenomatous 63 SSc 63 achieved sustained virologic 63 CrCl 63 IGFBP 63 systemic corticosteroid 63 mRCC 63 microsatellite instability 63 Histologic 63 low dose Iluvien 63 C1 INH deficiency 63 malignant polyps 63 HER2 positive metastatic breast 63 thromboembolic complications 63 mycophenolate mofetil 63 malignant lesions 63 Adjuvant therapy 63 melphalan prednisone 63 squamous intraepithelial lesions 63 GISTs 63 nodal metastases 63 pretreatment serum 63 Parathyroid Hormone 63 serum uric acid 63 INCB# [003]